Ultra-hypofractionated radiotherapy in early breast cancer: Experience in the Service of Dr. Enrique Gutiérrez CMDLT.

Abstract

OBJECTIVE: To present the results of our experience treating patients with early-stage breast cancer using Ultra-Hypofractionated Radiation Therapy (UFRT) at the Dr. Enrique Gutiérrez CMDLT service. METHOD: A single-center, retrospective, observational, and descriptive study was conducted during the period 2020 – 2025; Inclusion criteria were age ≥ 18 years, histology of invasive ductal carcinoma, ductal carcinoma in situ, or invasive lobular carcinoma, early stage T1-T2 (≤ 3 cm)/N0/M0, undergoing breast-conserving surgery +/- sentinel lymph node biopsy (SLN); any histological and molecular grade, with or without endocrine therapy. Patients received a total dose of 26 Gy in 5 fractions. RESULTS: Forty-two patients were included, with a median age of 68 years and a median follow-up of 22,3 months (range 0,5-59,8 months). Invasive ductal carcinoma was the most frequent histology (78,5%), with the Luminal A molecular subtype being present in 61,49%. Local control (LC) at 5 years was 97,6%, overall survival (OS) was 73,9%, cause-specific survival (CSS) was 100%, and distant metastasis-free survival (DMFS) was 92,3% Cosmetic results according to the RTOG were excellent in 73.8% of cases. CONCLUSIÓN: In our review, UFRT administration in patients with early breast cancer was shown to be safe and effective in LC, OS, CSS, and DMFS, with excellent cosmetic results and the advantage of being administered within 5 days. Our results are comparable to those obtained in the international literature.